Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-01 — Definition, Classification, and Pathophysiology Tier: Tier 1
1. A 58-year-old man with no prior cardiovascular disease, no diabetes, and a calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 6% presents with blood pressure readings of 136/84 mmHg confirmed on three separate office visits. Under the 2017 ACC/AHA hypertension guidelines, which of the following represents the most appropriate classification and initial management strategy?
A) Elevated blood pressure; recommend sodium restriction and aerobic exercise with follow-up in 3 months, as systolic BP below 140 mmHg does not meet the treatment threshold
B) Stage 2 hypertension; initiate dual antihypertensive therapy with an ACE inhibitor and a thiazide diuretic given the confirmed diastolic elevation
C) Normal blood pressure; the 140/90 mmHg threshold under JNC (Joint National Committee) 7 has not been met and no intervention is required under current standards
D) Stage 1 hypertension; recommend lifestyle modification and reassess in 3–6 months without initiating pharmacotherapy, as his ASCVD risk does not meet the threshold for drug treatment at this BP level
E) Stage 1 hypertension; initiate a thiazide diuretic immediately given confirmed elevation on three separate visits, which constitutes a compelling indication for pharmacotherapy regardless of risk level
ANSWER: D
Rationale:
This question asked you to apply the 2017 ACC/AHA classification and risk-stratified treatment threshold criteria. Option D is correct: 136/84 mmHg meets the Stage 1 hypertension definition (systolic 130–139 mmHg OR diastolic 80–89 mmHg). Pharmacotherapy at Stage 1 is indicated only when 10-year ASCVD risk is ≥10% or established cardiovascular disease is present. With a 6% risk and no high-risk features, the guideline-recommended approach is lifestyle modification — sodium restriction, aerobic exercise, weight management, dietary pattern changes — with reassessment in 3–6 months. Option A misclassifies the BP as merely elevated — elevated blood pressure is defined as systolic 120–129 with diastolic below 80; the diastolic of 84 mmHg confirms Stage 1, not just elevated. Option C applies the outdated JNC 7 threshold — the 2017 ACC/AHA guidelines are the current standard in the United States, and under those guidelines this patient has Stage 1 hypertension. Option E correctly classifies Stage 1 but incorrectly triggers immediate pharmacotherapy — treatment at Stage 1 is risk-stratified, and three confirmed visits do not constitute a compelling indication for drug treatment in a low-risk patient.
Option B: Option B incorrectly classifies the BP as Stage 2 (which requires systolic ≥140 OR diastolic ≥90) and recommends dual therapy, which is excessive for this BP level.
2. A 44-year-old woman with a 10-year ASCVD risk of 14% and a history of a prior ischemic stroke presents with sustained blood pressure of 134/82 mmHg. Under the 2017 ACC/AHA guidelines, which of the following most accurately describes the appropriate management approach?
A) Reassessment in 6 months is appropriate because her BP is below the ESC/ESH (European Society of Cardiology/European Society of Hypertension) 140/90 mmHg treatment threshold used in most international guidelines and does not warrant pharmacotherapy at this time
B) Pharmacotherapy is indicated because established cardiovascular disease — a prior ischemic stroke — places her in the high-risk category where drug treatment is recommended even at Stage 1 BP levels; her 10-year ASCVD risk of 14% provides a second independent justification
C) Dual antihypertensive therapy with an ACE inhibitor and calcium channel blocker is mandated by current guidelines in any patient with prior stroke and BP above 130 mmHg, regardless of risk stratification
D) Lifestyle modification alone is appropriate; her BP does not meet the Stage 1 pharmacotherapy threshold regardless of cardiovascular history because no individual drug class has been shown to prevent recurrent stroke
E) Pharmacotherapy is contraindicated within 12 months of a prior ischemic stroke due to risk of hypoperfusion injury during the period of ongoing ischemic penumbra recovery
ANSWER: B
Rationale:
This question asked you to apply the risk-stratified treatment framework of the 2017 ACC/AHA guidelines. Option B is correct: a prior ischemic stroke constitutes established cardiovascular disease, which — along with established coronary artery disease, peripheral arterial disease, and 10-year ASCVD risk ≥10% — is one of the criteria that triggers pharmacotherapy recommendation at Stage 1 hypertension (130–139/80–89 mmHg). Both criteria are independently met here: established CVD (prior stroke) and ASCVD risk of 14% exceeding the 10% threshold. Initiating antihypertensive therapy in this patient is clearly indicated. Option E is fabricated — there is no guideline-based contraindication to antihypertensive therapy within 12 months of ischemic stroke; long-term BP lowering is recommended for secondary prevention.
Option A: Option A is incorrect — while the ESC/ESH guidelines do use a 140/90 mmHg threshold, clinical practice in the United States follows the 2017 ACC/AHA framework, under which this patient has Stage 1 hypertension with clear indications for pharmacotherapy.
Option C: Option C is incorrect — there is no mandate for a specific drug combination at this BP level; agent selection depends on comorbidities and tolerability, and dual therapy is not required at Stage 1.
Option D: Option D is incorrect — lifestyle modification alone is appropriate at Stage 1 only in patients without established CVD and with ASCVD risk below 10%; this patient meets neither condition, and evidence strongly supports BP lowering for secondary stroke prevention.
3. A 67-year-old man with long-standing hypertension presents with progressive dyspnea on exertion. Echocardiography reveals an ejection fraction of 58%, concentric left ventricular hypertrophy, grade II diastolic dysfunction, and left atrial enlargement. Which of the following best describes the pathophysiological sequence linking his hypertension to these findings?
A) Sustained pressure overload from chronic hypertension causes direct trophic effects of Ang II and aldosterone on cardiomyocytes, producing concentric left ventricular hypertrophy (LVH); the hypertrophied, fibrotic myocardium impairs ventricular relaxation and filling, producing diastolic dysfunction and HFpEF, while left atrial enlargement reflects chronically elevated filling pressures transmitted upstream
B) Chronic hypertension reduces coronary perfusion pressure through arteriolar vasoconstriction, producing ischemic cardiomyopathy that manifests as concentric LVH followed by reduced EF and systolic dysfunction
C) Left atrial enlargement in hypertension is caused by direct aldosterone-mediated atrial fibrosis that is independent of LV filling pressures, while LVH and diastolic dysfunction develop through separate RAAS-independent pathways
D) Hypertension causes diastolic dysfunction primarily through volume overload and sodium retention, which stretches the LV wall and produces eccentric rather than concentric hypertrophy
E) These findings are most consistent with hypertrophic obstructive cardiomyopathy rather than hypertensive heart disease, as diastolic dysfunction with preserved EF is not a feature of sustained pressure overload
ANSWER: A
Rationale:
This question asked you to trace the cardiac pathophysiological sequence of chronic hypertension. Option A is correct and describes the complete mechanistic chain: sustained systemic hypertension imposes chronically elevated afterload on the left ventricle. The LV responds through concentric hypertrophy — wall thickening without chamber dilation — driven by mechanical pressure loading and direct trophic stimulation by Ang II (activating MAP kinase and TGF-β (transforming growth factor-beta) signaling) and aldosterone (promoting interstitial fibrosis through mineralocorticoid receptors on cardiac fibroblasts). The hypertrophied, fibrotic myocardium becomes stiffer and slower to relax — producing diastolic dysfunction. With preserved systolic function (EF 58%), this is HFpEF. Chronically elevated LV filling pressures are transmitted to the left atrium, causing left atrial dilation and fibrosis — the arrhythmogenic substrate for atrial fibrillation.
Option B: Option B incorrectly describes ischemic cardiomyopathy — hypertension accelerates atherosclerosis and increases coronary demand, but does not reduce coronary perfusion pressure through arteriolar vasoconstriction.
Option C: Option C incorrectly separates aldosterone-mediated atrial fibrosis from LV filling pressures — left atrial enlargement is primarily a consequence of elevated filling pressures from the stiff LV.
Option E: Option E is incorrect — HFpEF with diastolic dysfunction and concentric LVH is the classic cardiac consequence of long-standing hypertension; hypertrophic obstructive cardiomyopathy has a distinct genetic pathophysiology.
4. A 52-year-old man with hypertension, type 2 diabetes, eGFR of 52 mL/min/1.73m², and urine albumin-to-creatinine ratio of 68 mg/g has BP of 144/88 mmHg on lifestyle modification alone. Which of the following most accurately reflects the pharmacological rationale for agent selection in this patient?
A) Beta-blocker therapy is the preferred initial agent because diabetes-related autonomic neuropathy increases sympathetic tone and beta-1 selective blockade addresses both the hypertension and the neurogenic mechanism
B) Diuretic therapy should be first because his reduced eGFR indicates volume expansion as the dominant mechanism driving hypertension and a loop diuretic most directly addresses this
C) ACE inhibitor or ARB therapy is preferred because RAAS blockade reduces intraglomerular pressure through preferential efferent arteriole vasodilation, slows progression of diabetic nephropathy, and reduces albuminuria independently of systemic BP reduction — addressing the pharmacological target aligned with both his hypertension and his kidney disease
D) Calcium channel blocker therapy is contraindicated in the presence of diabetic nephropathy because dihydropyridine CCBs increase intraglomerular pressure and are absolutely contraindicated in patients with both diabetes and CKD
E) Antihypertensive therapy should be deferred until his eGFR falls below 30 mL/min/1.73m² because earlier aggressive BP lowering accelerates the rate of nephron loss by reducing the adaptive hyperfiltration that compensates for existing nephron loss
ANSWER: C
Rationale:
This question asked you to apply the principle of mechanism-targeted drug selection when hypertension co-exists with diabetic nephropathy. Option C is correct: in a patient with hypertension, diabetes, and albuminuric CKD, ACE inhibitors and ARBs are the preferred first-line agents because they address the underlying renal mechanism. Diabetic nephropathy is driven substantially by glomerular hypertension — elevated intraglomerular pressure damages the filtration barrier, causing progressive podocyte loss and albuminuria. RAAS blockade preferentially dilates the efferent arteriole, reducing intraglomerular hydraulic pressure independently of systemic BP reduction. Large randomized trials (RENAAL (a landmark trial of losartan in type 2 diabetic nephropathy), IDNT (irbesartan in type 2 diabetic nephropathy), MICROHOPE (ramipril in diabetic patients from the HOPE trial)) demonstrated that RAAS inhibitors reduce the rate of GFR decline and end-stage renal disease (ESRD) in diabetic nephropathy beyond what BP reduction alone would predict. Option E is fabricated and dangerous — deferring antihypertensive therapy until late CKD would allow preventable progression; early aggressive BP control with RAAS blockade is the standard of care.
Option A: Option A is incorrect — beta-blockers do not have a specific renoprotective indication in diabetic nephropathy and are not preferred as first-line antihypertensives in this setting.
Option B: Option B is incorrect — while diuretics are useful in volume-expanded CKD, they are not preferred as the initial agent when albuminuric diabetic nephropathy is present; RAAS blockade takes priority based on evidence.
Option D: Option D is incorrect — while there are concerns about CCBs increasing intraglomerular pressure when used without RAAS blockade, they are not absolutely contraindicated in diabetic nephropathy and are commonly used as add-on therapy.
5. A 39-year-old lean woman (BMI 22) with no family history of hypertension presents with confirmed BP of 168/104 mmHg and unprovoked hypokalemia (K+ 3.1 mEq/L). She takes no diuretics. Her only medication is an oral contraceptive. Which of the following represents the most appropriate next diagnostic step?
A) Initiate dual antihypertensive therapy immediately; no workup is needed because primary hypertension accounts for 90–95% of all cases and the likelihood of a secondary cause does not justify delaying treatment
B) Obtain a renal artery duplex Doppler ultrasound to evaluate for renovascular hypertension, which is the most common secondary cause in young women and is the most specific match for this clinical profile
C) Perform echocardiography to assess for left ventricular hypertrophy, which would confirm the chronicity of hypertension and guide treatment intensity
D) Obtain plasma aldosterone concentration and plasma renin activity to calculate the aldosterone-to-renin ratio, as the combination of young age, lean build, absent family history, severe hypertension, and unprovoked hypokalemia without diuretic use is the classic biochemical profile of primary aldosteronism
E) Discontinue the oral contraceptive and reassess blood pressure in 4 weeks, as oral contraceptive pill (OCP)-induced hypertension is the most common secondary cause in this demographic and always resolves within 1 month of discontinuation
ANSWER: D
Rationale:
This question asked you to identify the most diagnostically specific workup based on the strongest clinical clues. Option D is correct: the combination of young, lean patient without family history of hypertension, severe hypertension, and — critically — unprovoked hypokalemia (K+ 3.1 mEq/L) without diuretic use is the biochemical fingerprint of primary aldosteronism. Autonomous aldosterone secretion causes sodium retention (hypertension), potassium wasting (hypokalemia), and suppresses renin through negative feedback. The aldosterone-to-renin ratio (ARR) is the first-line screening test; an ARR above 30 (ng/dL)/(ng/mL/hr) with an elevated aldosterone level is highly sensitive for primary aldosteronism. Oral contraceptives can cause hypertension but do not cause unprovoked hypokalemia — the hypokalemia is the key discriminating clue that makes primary aldosteronism the priority diagnosis. Option E is partially reasonable in that OCPs should eventually be discontinued, but it does not address the hypokalemia, which is not explained by OCP use and which demands urgent investigation.
Option A: Option A is incorrect — the hypokalemia is unexplained by primary hypertension and demands secondary workup; deferring to empirical treatment would miss a potentially curable diagnosis.
Option B: Option B is incorrect — renovascular hypertension in young women (fibromuscular dysplasia) is associated with elevated renin, not hypokalemia; renovascular disease is not the most specific match for this profile.
Option C: Option C is incorrect — echocardiography assesses the consequence of hypertension, not its cause; it does not help differentiate primary from secondary hypertension.
6. A 61-year-old man with hypertension presents with sudden severe headache, BP 224/138 mmHg, confusion, bilateral papilledema with flame hemorrhages and cotton-wool spots, and creatinine risen from 1.0 to 2.8 mg/dL over 72 hours. Which of the following most accurately describes the pathophysiological mechanism responsible for his neurological and renal deterioration?
A) Acute left ventricular failure from hypertensive LVH has reduced cerebral and renal perfusion to ischemic levels, producing neurological and renal findings simultaneously through cardiogenic shock
B) Failure of cerebral and renal autoregulation at extreme BP levels results in pressure-passive hyperperfusion — vasogenic edema in the brain (hypertensive encephalopathy/PRES (posterior reversible encephalopathy syndrome)) and fibrinoid necrosis of renal arterioles (malignant nephrosclerosis) — constituting a hypertensive emergency requiring controlled BP reduction
C) Bilateral papilledema indicates raised intracranial pressure from a space-occupying lesion compressing the carotid arteries, producing reactive hypertension — the elevated BP is a consequence of intracranial hypertension rather than its cause
D) The renal deterioration represents a separate coincidental process — likely contrast nephropathy from recent imaging — that is unrelated to the hypertensive emergency
E) Hypertensive encephalopathy is mediated by cerebral vasospasm causing ischemia rather than hyperperfusion; the appropriate treatment is cerebral vasodilator therapy, not antihypertensive agents
ANSWER: B
Rationale:
This question asked you to identify the pathophysiological mechanism underlying hypertensive emergency with multi-organ involvement. Option B is correct: the presentation — extreme hypertension with papilledema, neurological changes, and acute kidney injury — is a hypertensive emergency. At very high BP levels, the upper limit of cerebrovascular autoregulation is breached; the cerebral vasculature can no longer maintain constant perfusion despite rising systemic pressure. Vasogenic edema develops (the mechanism of posterior reversible encephalopathy syndrome, PRES) as the blood-brain barrier is disrupted by pressure-passive hyperperfusion. In the kidney, extreme BP produces fibrinoid necrosis of afferent arterioles and glomerular capillaries — malignant nephrosclerosis. Cotton-wool spots represent ischemic axonal swelling from arteriolar occlusion; flame hemorrhages and papilledema confirm the severity of microvascular injury. The clinical imperative is controlled BP reduction — target mean arterial pressure (MAP) reduction of 10–20% in the first hour, then further over 24 hours — not rapid normalization, which risks ischemic injury to organs adapted to high pressure. Option D is fabricated — there is no mention of contrast exposure, and coincidental presentation is not the appropriate clinical reasoning.
Option A: Option A is incorrect — cardiogenic shock does not explain the funduscopic findings; the pattern is characteristic of direct hypertensive microvascular injury, not reduced cardiac output.
Option C: Option C is incorrect — while a space-occupying lesion can cause raised intracranial pressure (ICP) and Cushing's reflex, the clinical pattern here is characteristic of hypertensive emergency, not reactive hypertension from intracranial mass.
Option E: Option E is incorrect — hypertensive encephalopathy is caused by hyperperfusion and vasogenic edema, not vasospasm; treatment is carefully controlled BP lowering.
7. A 48-year-old obese man (BMI 38) with type 2 diabetes and hypertension has BP persistently above 150/96 mmHg despite maximum doses of an ACE inhibitor and a calcium channel blocker. He snores heavily and his partner reports witnessed apneas. Which of the following most accurately explains the inadequate BP control, and what is the most important missing element of his antihypertensive regimen?
A) ACE inhibitors are ineffective in obese patients because adipose tissue sequesters the drug before systemic absorption, reducing bioavailability to therapeutically inadequate levels
B) The ACE inhibitor and CCB are pharmacologically antagonistic — ACE inhibitor-mediated efferent vasodilation counteracts CCB-mediated afferent vasodilation, producing a net null hemodynamic effect that explains the treatment failure
C) His hypertension has multiple active neurohormonal drivers — obesity-driven sympathetic nervous system (SNS) activation and RAAS upregulation, obstructive sleep apnea (OSA)-mediated nocturnal catecholamine surges that persist as daytime sympathetic hyperactivation, and direct hypoxia-driven aldosterone secretion — but his regimen targets these mechanisms adequately and the treatment failure is idiosyncratic
D) Resistant hypertension in this patient most likely reflects volume expansion from aldosterone excess and sodium retention that his regimen does not address — the 2017 ACC/AHA definition of resistant hypertension requires BP above goal on three agents including a diuretic, and the absence of a diuretic is the most actionable gap in his current regimen
E) The combination of obesity and OSA activates the parathyroid hormone axis, causing secondary hyperparathyroidism that directly raises BP through calcium-mediated vasoconstriction, and the appropriate next step is measurement of serum parathyroid hormone (PTH) and calcium
ANSWER: D
Rationale:
This question asked you to identify the mechanism of resistant hypertension and the most important missing pharmacological element. Option D is correct: the 2017 ACC/AHA guidelines define resistant hypertension as BP above goal despite three antihypertensive agents from different classes, where at least one is a diuretic, at optimal doses. This patient is on two agents — an ACE inhibitor and a CCB — with no diuretic. In obese patients with OSA and diabetes, hypertension is driven by multiple pathways including volume expansion from obesity-related RAAS upregulation, direct aldosterone excess driven by hypoxia-inducible pathways, and SNS hyperactivation. Volume control via a diuretic (typically a thiazide or chlorthalidone as first choice, a loop diuretic if eGFR is significantly reduced) is a critical missing element. Without addressing volume, the sodium-retaining neurohormonal pathways will continue to counteract vasodilator therapy. Option A is pharmacologically incorrect — ACE inhibitors are not sequestered by adipose tissue; their bioavailability is not clinically reduced by obesity. Option B is pharmacologically fabricated — ACE inhibitor plus CCB is one of the most evidence-based and guideline-recommended combinations for hypertension; they are complementary, not antagonistic. Option E is fabricated — secondary hyperparathyroidism is not a recognized major mechanism of obesity/OSA-related hypertension, and PTH measurement is not the appropriate next step.
Option C: Option C incorrectly concludes the regimen is adequate — it is not; the missing diuretic is a clear addressable gap.
8. A 55-year-old man with hypertension controlled at 128/78 mmHg on an ACE inhibitor undergoes echocardiography for a separate indication. It reveals mild concentric left ventricular hypertrophy (LV mass index 118 g/m²). Which of the following best explains why LVH detection changes his clinical assessment beyond the fact that his BP appears controlled?
A) LVH is a benign adaptive response to prior pressure overload that resolves spontaneously now that BP is controlled, and it does not require any additional clinical action or change in treatment intensity
B) LVH detection in a patient with controlled BP indicates the presence of a secondary cause of hypertension, as primary hypertension does not produce LVH when BP is adequately treated
C) LVH does not change management because the current BP target of less than 130/80 mmHg is already guideline-appropriate for hypertensive patients regardless of end-organ damage status
D) LVH detection in a hypertensive patient should prompt reassessment of the serum aldosterone-to-renin ratio to exclude primary aldosteronism, as LVH is pathognomonic for the direct trophic effects of aldosterone on the myocardium rather than pressure overload
E) LVH in a hypertensive patient constitutes detected target organ damage — an independent cardiovascular risk factor associated with increased risk of ventricular arrhythmia, diastolic heart failure, atrial fibrillation, and sudden death — that may justify intensification of RAAS-targeted therapy and warrants monitoring for LVH regression, as regression with treatment is associated with improved outcomes independent of BP lowering
ANSWER: E
Rationale:
This question asked you to identify the clinical significance of LVH detection in a hypertensive patient with apparently controlled BP. Option E is correct: LVH is not a benign incidental finding — it is a manifestation of hypertensive target organ damage and an independent cardiovascular risk factor beyond the blood pressure level itself. LVH is associated with increased risk of ventricular arrhythmias (both fatal and non-fatal), diastolic dysfunction progressing to HFpEF, atrial fibrillation (the arrhythmogenic substrate created by fibrotic myocardial remodeling), and sudden cardiac death. Critically, regression of LVH with antihypertensive therapy — demonstrated most consistently with RAAS inhibitors and to a lesser extent with other drug classes — is associated with reduction in these outcomes independent of the degree of BP lowering. Detection of LVH may justify intensification of therapy even when BP appears controlled at target, and it mandates monitoring for regression.
Option A: Option A is incorrect — LVH is not benign and does not resolve spontaneously; it requires active clinical attention.
Option B: Option B is incorrect — primary hypertension absolutely causes LVH; this is in fact one of its most characteristic target organ effects.
Option C: Option C is incorrect — the presence of detected target organ damage is one of the factors informing individualized treatment decisions; it is not irrelevant to management.
Option D: Option D is incorrect — while primary aldosteronism does promote myocardial fibrosis through direct mineralocorticoid effects, LVH is not pathognomonic for aldosteronism and is extremely common in pressure overload from primary hypertension.
9. A 72-year-old woman with isolated systolic hypertension (BP 162/68 mmHg, pulse pressure 94 mmHg) presents for medication initiation. Which of the following best explains why her widened pulse pressure is mechanistically distinct from combined systolic-diastolic hypertension in younger adults?
A) Her widened pulse pressure reflects increased cardiac stroke volume from age-related sympathetic hyperactivation — the same mechanism as combined HTN in younger patients but amplified by reduced cardiac reserve
B) Her widened pulse pressure is caused by aortic valve incompetence, which is the dominant mechanism of isolated systolic hypertension (ISH) in elderly women and should be excluded before initiating antihypertensive therapy
C) Age-related stiffening of large conduit arteries increases pulse wave velocity, causing the reflected pressure wave to return to the central aorta during systole — augmenting the systolic pressure peak — rather than during diastole where it normally cushions diastolic pressure via the Windkessel effect, simultaneously elevating systolic blood pressure (SBP) and reducing diastolic blood pressure (DBP)
D) Her widened pulse pressure reflects impaired renal sodium excretion from nephrosclerosis causing selective systolic volume loading, which increases stroke volume without meaningfully affecting vascular tone or diastolic pressure
E) Widened pulse pressure in elderly women is primarily a consequence of estrogen deficiency causing endothelial dysfunction, and hormone replacement therapy should be initiated to restore vascular compliance before antihypertensive agents are considered
ANSWER: C
Rationale:
This question asked you to explain the vascular mechanism specifically responsible for ISH and widened pulse pressure in elderly patients. Option C is correct: the key distinction is arterial stiffness and its effect on the pressure wave. In younger adults, the aorta and large conduit vessels are compliant — they absorb systolic ejection energy by expanding during systole (buffering the SBP peak) and recoil during diastole (sustaining diastolic pressure and coronary perfusion) — the Windkessel effect. The reflected pressure wave from peripheral resistance sites returns centrally during diastole in compliant vessels. With aging, elastin fragmentation, collagen cross-linking, and vascular calcification stiffen these vessels: pulse wave velocity increases; the reflected wave returns to the central aorta during systole rather than diastole, adding to the systolic peak and raising SBP; and the loss of elastic recoil reduces diastolic pressure, producing the characteristically widened pulse pressure of ISH. This mechanism is entirely distinct from the increased total peripheral resistance (TPR) that drives combined systolic-diastolic hypertension in younger patients.
Option A: Option A is incorrect — sympathetic hyperactivation increases CO but would raise both systolic and diastolic pressure, not produce selective systolic elevation with reduced diastolic.
Option B: Option B is incorrect — aortic valve incompetence does produce wide pulse pressure, but it is not the dominant mechanism of ISH in elderly patients and should not delay antihypertensive therapy without specific clinical evidence.
Option D: Option D is incorrect — renal sodium retention causes volume-dependent hypertension affecting both pressures.
Option E: Option E is incorrect — while estrogen deficiency contributes to vascular aging, hormone replacement therapy carries cardiovascular risks and is not a first-line antihypertensive strategy.
10. A 46-year-old man presents with BP 178/112 mmHg. Biochemical testing reveals suppressed plasma renin activity (0.4 ng/mL/hr), elevated plasma aldosterone (28 ng/dL), ARR of 70, and serum potassium of 2.9 mEq/L. CT of the adrenal glands reveals a 1.8 cm right adrenal nodule. He is a surgical candidate. Which of the following represents the most important next step in management?
A) Proceed directly to laparoscopic right adrenalectomy based on CT identification of the nodule — in a young surgical candidate with biochemically confirmed primary aldosteronism, CT localization is sufficient to determine laterality
B) Initiate spironolactone for BP and potassium control while scheduling adrenal vein sampling (AVS) to confirm lateralization before any surgical decision, because CT cannot reliably distinguish a unilateral aldosterone-producing adenoma from a nonfunctioning incidentaloma with contralateral bilateral hyperplasia
C) Initiate an ACE inhibitor to suppress Ang II-driven aldosterone secretion from the nodule, correcting both the hypertension and the hypokalemia before definitive imaging
D) Repeat the aldosterone-to-renin ratio under standardized conditions before proceeding, as a ratio of 70 likely reflects posture artifact and requires confirmation before the finding is considered clinically valid
E) Order 24-hour urinary catecholamines to exclude pheochromocytoma before adrenal-focused management, as pheochromocytoma and aldosteronoma cannot be reliably distinguished by adrenal CT morphology alone
ANSWER: B
Rationale:
This question asked you to identify the critical next step after CT imaging in biochemically confirmed primary aldosteronism. Option B is correct: once biochemical testing confirms primary aldosteronism and the patient is a surgical candidate, adrenal vein sampling (AVS) is the gold-standard procedure to lateralize aldosterone excess — distinguishing between a unilateral aldosterone-producing adenoma (potentially cured by adrenalectomy) and bilateral adrenal hyperplasia (medically managed with mineralocorticoid receptor (MR) antagonists). CT imaging is unreliable for this distinction: small adenomas are frequently missed, nonfunctioning incidentalomas on the same side as the CT finding may be mistaken for the source, and bilateral hyperplasia can appear radiologically normal. The Endocrine Society guidelines recommend AVS for all surgical candidates with confirmed primary aldosteronism. Spironolactone is initiated concurrently to control BP and correct hypokalemia while AVS is arranged.
Option A: Option A is incorrect — proceeding directly to surgery based on CT alone would be inappropriate; studies show CT misidentifies the correct surgical side in a substantial proportion of patients.
Option C: Option C is incorrect — ACE inhibitors do not suppress autonomous aldosterone secretion; primary aldosteronism is independent of Ang II, which is why upstream RAAS blockade does not correct it.
Option D: Option D is incorrect — an ARR of 70 with a suppressed renin and elevated aldosterone represents clear biochemical confirmation; repeat testing is not indicated at this stage.
Option E: Option E is incorrect — pheochromocytoma and primary aldosteronism have distinct biochemical signatures and are not confused by the aldosterone-renin workup described; catecholamine testing is not indicated here.
11. A 63-year-old man with hypertension, CKD stage 3a (eGFR 52), and microalbuminuria is started on an ACE inhibitor. Two weeks later his potassium is 5.6 mEq/L and creatinine has risen from 1.4 to 1.9 mg/dL (36% increase). He is asymptomatic. Which of the following most accurately characterizes these findings and guides the appropriate clinical response?
A) Both findings represent idiosyncratic adverse drug reactions to the ACE inhibitor that are unpredictable, not mechanistically related to its pharmacology, and mandate permanent discontinuation before serious nephrotoxicity develops
B) The potassium rise reflects direct tubular toxicity on the distal nephron from ACE inhibitor accumulation in CKD — a toxic mechanism unrelated to aldosterone suppression that requires immediate drug cessation
C) The creatinine rise above 30% from baseline is diagnostic of bilateral renal artery stenosis newly unmasked by efferent vasodilation; the ACE inhibitor must be stopped and renovascular imaging initiated immediately
D) A modest creatinine rise (up to 30%) and mild hyperkalemia are anticipated pharmacodynamic effects of ACE inhibitor initiation in CKD patients reflecting reduced intraglomerular pressure and aldosterone suppression; a 36% rise and potassium of 5.6 mEq/L warrant careful clinical assessment and management rather than automatic drug discontinuation, and should be weighed against the long-term renoprotective benefit
E) The hyperkalemia is caused by ACE inhibitor-induced metabolic alkalosis that shifts potassium extracellularly, and the appropriate initial response is sodium bicarbonate supplementation to correct the alkalosis before reconsidering drug continuation
ANSWER: D
Rationale:
This question asked you to interpret the expected pharmacodynamic effects of ACE inhibitor initiation in a CKD patient. Option D is correct: in CKD patients initiating ACE inhibitor therapy, a modest creatinine rise is an expected pharmacodynamic effect reflecting the intended reduction in intraglomerular pressure — efferent arteriole dilation reduces the hydraulic pressure driving filtration, transiently lowering measured GFR. This does not represent nephrotoxicity; it represents the mechanism through which RAAS blockade protects the glomerulus from long-term pressure injury. Similarly, mild hyperkalemia is expected because reduced aldosterone decreases renal potassium excretion. The conventional threshold for concern is a creatinine rise above 30%; this patient is at 36% — slightly above threshold — and a potassium of 5.6 mEq/L warrants close attention. The appropriate response is careful management: reduce dietary potassium, review other potassium-elevating medications, consider adding a low-dose loop diuretic for both volume and potassium control, and recheck in 1–2 weeks. Automatic discontinuation at this threshold would deny the patient the demonstrated long-term renoprotective benefit of RAAS blockade. Option E is fabricated — ACE inhibitors cause a mild metabolic acidosis in CKD through reduced aldosterone, not metabolic alkalosis.
Option A: Option A is incorrect — these findings are entirely predictable pharmacodynamic effects, not idiosyncratic reactions.
Option B: Option B is incorrect — the hyperkalemia is caused by aldosterone suppression, not direct tubular toxicity.
Option C: Option C is incorrect — a 36% creatinine rise in a CKD patient starting an ACE inhibitor is a common finding that does not confirm bilateral renal artery stenosis without additional clinical features (more dramatic rise, failure to stabilize, or relevant history).
12. A 58-year-old woman with hypertension and a 20-year history of type 2 diabetes has eGFR 44 mL/min/1.73m² and urine albumin-to-creatinine ratio (ACR) 420 mg/g. Her BP is 148/92 mmHg on amlodipine 10 mg daily. Beyond the fact that her BP remains above goal, which of the following best explains why amlodipine monotherapy is insufficient as the sole antihypertensive strategy in this patient?
A) Amlodipine is directly nephrotoxic in diabetic nephropathy through calcium overload of podocytes at therapeutic plasma concentrations, independently of any hemodynamic effect
B) Dihydropyridine CCBs preferentially dilate the afferent arteriole without equivalent efferent dilation, potentially increasing intraglomerular pressure — the opposite of what is needed in diabetic nephropathy where reducing intraglomerular pressure is the therapeutic priority that RAAS blockade specifically addresses
C) Amlodipine causes reflex RAAS activation through sympathetic stimulation that directly accelerates diabetic nephropathy independently of blood pressure by increasing Ang II-mediated TGF-β production in the glomerulus
D) Calcium channel blockers reduce renal prostaglandin E2 synthesis, eliminating the afferent arteriole autoregulatory protection of the glomerulus and worsening proteinuria in all diabetic patients at any dose
E) Amlodipine is ineffective in patients with eGFR below 50 because renal CYP3A4 enzymes are responsible for its primary metabolism and CKD reduces drug clearance, causing accumulation and paradoxical vasoconstrictive side effects
ANSWER: B
Rationale:
This question asked you to identify the mechanistic limitation of CCB monotherapy in diabetic nephropathy. Option B is correct: in diabetic nephropathy, glomerular injury is driven substantially by intraglomerular hypertension. The therapeutic goal is to reduce this intraglomerular pressure, which RAAS blockade achieves by preferentially dilating the efferent arteriole. Dihydropyridine CCBs dilate the afferent arteriole (reducing pre-glomerular resistance) but do not produce equivalent efferent vasodilation. The net hemodynamic consequence in the glomerulus is that reduced afferent resistance allows more systemic pressure to be transmitted into the glomerular capillaries, potentially increasing intraglomerular pressure despite lowering systemic BP. This is why dihydropyridine CCBs alone do not provide the same degree of glomerular protection as RAAS blockade and may modestly worsen proteinuria when used without RAAS inhibition. Adding an ACE inhibitor or ARB to amlodipine addresses both the systemic BP goal and the intraglomerular pressure target.
Option A: Option A is incorrect — CCBs are not directly nephrotoxic at therapeutic doses; they are used safely as add-on therapy in CKD.
Option C: Option C overstates the clinical significance of reflex RAAS activation with CCBs — modest reflex renin release with dihydropyridines is not the primary mechanistic concern in diabetic nephropathy management.
Option D: Option D is incorrect — CCBs do not meaningfully impair renal prostaglandin synthesis.
Option E: Option E is incorrect — amlodipine is hepatically metabolized by CYP3A4, not renally cleared; it does not accumulate in CKD and is not contraindicated at reduced eGFR.
13. A 34-year-old woman at 26 weeks of gestation presents with BP 156/102 mmHg on two readings 4 hours apart, 2+ proteinuria, headache, and visual blurring. Regarding the pharmacological management of her hypertension, which of the following is most accurate?
A) ACE inhibitors are the preferred agents in gestational hypertension because RAAS blockade reduces placental aldosterone production and prevents progression to eclampsia without fetal risk in the second trimester
B) Antihypertensive therapy should be withheld until BP exceeds 180/120 mmHg in pregnancy because moderate BP reduction at this gestational age carries higher risk of placental insufficiency than severe hypertension
C) Methyldopa, labetalol, and extended-release nifedipine are acceptable antihypertensive agents in this setting; ACE inhibitors and ARBs are contraindicated in pregnancy due to fetal renal tubular dysplasia, anuria, oligohydramnios, pulmonary hypoplasia, and skull ossification defects — a class-wide teratogenic effect mediated by fetal RAAS blockade during critical periods of renal development
D) Beta-blockers are contraindicated throughout pregnancy because fetal beta-2 receptor blockade causes irreversible bronchopulmonary dysplasia in the developing fetal lung
E) Intravenous hydralazine must be used as the sole antihypertensive agent in severe preeclampsia because it is the only agent with proven fetal safety; all oral agents are contraindicated until delivery
ANSWER: C
Rationale:
This question asked you to apply the pharmacological principles governing antihypertensive therapy in pregnancy. Option C is correct on both counts: methyldopa (the historical standard with the longest safety record), labetalol (a combined alpha/beta-blocker), and extended-release nifedipine (a dihydropyridine CCB) are the accepted first-line antihypertensive options in pregnancy. ACE inhibitors and ARBs are absolutely contraindicated after the first trimester. They carry a black-box warning for fetal harm: fetal RAAS blockade during critical periods of renal development causes renal tubular dysplasia, fetal anuria, oligohydramnios, pulmonary hypoplasia from reduced fetal lung fluid, and calvaria (skull) hypoplasia. This is a class-wide teratogenic effect applying to all ACE inhibitors and all ARBs.
Option A: Option A is incorrect and dangerous — ACE inhibitors are contraindicated in pregnancy and must not be used regardless of the indication.
Option B: Option B is incorrect — severe hypertension in pregnancy (BP ≥160/110 mmHg) requires urgent treatment; withholding therapy until 180/120 mmHg exposes the mother to risk of hemorrhagic stroke.
Option D: Option D is incorrect — labetalol, a beta-blocker, is one of the first-line agents in gestational hypertension; while intrauterine beta-blocker exposure can cause neonatal bradycardia and hypoglycemia requiring monitoring, it does not cause irreversible bronchopulmonary dysplasia and is not contraindicated throughout pregnancy.
Option E: Option E is incorrect — multiple oral agents are used safely in gestational hypertension; IV hydralazine is not the sole safe option and is not universally preferred.
14. A 29-year-old man with confirmed pheochromocytoma (elevated plasma free metanephrines, 4.2 cm right adrenal mass on CT) is scheduled for laparoscopic adrenalectomy in 3 weeks. Which of the following correctly describes the required pharmacological preparation before surgical resection?
A) Beta-blocker therapy alone (propranolol 40 mg twice daily) should be initiated immediately to prevent intraoperative hypertensive crises by blocking adrenergic receptor stimulation from catecholamine release during tumor manipulation
B) Alpha-blockade must be established first and maintained for at least 10–14 days preoperatively before any beta-blocker is added; phenoxybenzamine or doxazosin are the standard agents; adding a beta-blocker before adequate alpha-blockade is in place leaves alpha-1-mediated vasoconstriction unopposed and risks precipitating a hypertensive crisis
C) No pharmacological preparation is required before laparoscopic adrenalectomy because minimally invasive technique eliminates intraoperative catecholamine release from tumor manipulation
D) Alpha and beta blockade should be initiated simultaneously on the same day; the relative sequencing of alpha versus beta receptor blockade does not affect perioperative hemodynamic stability
E) ACE inhibitors are the preferred preoperative agents because pheochromocytoma-related hypertension is primarily RAAS-mediated through catecholamine stimulation of renin secretion, and RAAS blockade addresses the mechanism more directly than adrenergic receptor blockade
ANSWER: B
Rationale:
This question asked you to identify the correct sequence and rationale of preoperative pharmacological preparation for pheochromocytoma. Option B is correct: alpha-adrenergic blockade must be established first and for an adequate duration before surgery. The mechanism is critical: pheochromocytoma produces catecholamines (norepinephrine, epinephrine) that cause hypertension primarily through alpha-1 receptor-mediated vasoconstriction. Intraoperative tumor manipulation triggers massive catecholamine release. If beta-blockade is initiated before alpha-blockade is established, the beta-2-mediated vasodilation that partially counteracts catecholamine-driven vasoconstriction is eliminated, leaving alpha-1 vasoconstriction unopposed — a potentially fatal sequence. Alpha-blockade first also allows vascular resistance to fall and permits volume repletion (catecholamine-mediated vasoconstriction causes relative hypovolemia). Phenoxybenzamine (irreversible non-selective alpha blocker, providing durable blockade) or doxazosin (selective alpha-1 competitive antagonist) are standard.
Option A: Option A is incorrect and dangerous — beta-blockade alone before alpha-blockade is established is contraindicated in pheochromocytoma.
Option C: Option C is incorrect — pharmacological preparation is mandatory regardless of surgical approach; laparoscopic technique does not eliminate catecholamine surges.
Option D: Option D is incorrect — the sequential requirement (alpha first, beta second) is a patient safety principle, not a preference.
Option E: Option E is incorrect — pheochromocytoma hypertension is primarily catecholamine-mediated, not RAAS-mediated; ACE inhibitors are not appropriate preoperative agents.
15. A 66-year-old man with hypertension develops creatinine rise from 1.2 to 3.1 mg/dL within 5 days of starting an ACE inhibitor. Bilateral renal artery stenosis is confirmed on Doppler ultrasound. The ACE inhibitor is discontinued and creatinine returns toward baseline. Which of the following best describes the appropriate long-term antihypertensive strategy?
A) ARBs can be safely substituted for the ACE inhibitor because ARBs block the AT1 (angiotensin type 1) receptor rather than preventing Ang II formation, and this downstream pharmacological distinction eliminates the efferent vasodilation mechanism that caused the AKI
B) ACE inhibitors at very low doses can be reintroduced with careful monitoring because partial efferent vasodilation at low doses provides net glomerular protection even in bilateral renal artery stenosis, and the renoprotective benefit outweighs the risk
C) Surgical revascularization or renal artery stenting eliminates the need for antihypertensive pharmacotherapy in all patients with bilateral renal artery stenosis once procedural success is confirmed
D) Beta-blockers alone are sufficient for long-term management because they lower BP by reducing renin secretion from the stenotic kidney, addressing the causal mechanism without affecting intraglomerular efferent pressure
E) Calcium channel blockers and thiazide or loop diuretics are preferred antihypertensive agents in this setting because they lower systemic BP through mechanisms that do not depend on efferent arteriolar tone, avoiding the intraglomerular pressure collapse that RAAS blockade causes when compensatory efferent constriction is the only mechanism maintaining GFR
ANSWER: E
Rationale:
This question asked you to identify the correct antihypertensive strategy when RAAS blockade is contraindicated. Option E is correct: the fundamental problem in bilateral renal artery stenosis is that GFR maintenance depends on Ang II-mediated efferent arteriole constriction as a compensatory mechanism. Both ACE inhibitors and ARBs eliminate this compensation through different points on the same RAAS pathway — ACE inhibitors prevent Ang II formation; ARBs block its AT1 receptor action — and both are therefore equally contraindicated in bilateral renal artery stenosis. The safe antihypertensive options are agents that lower systemic BP without compromising efferent compensatory tone: dihydropyridine calcium channel blockers (which reduce afferent resistance and systemic vascular resistance without direct efferent effects), diuretics (which reduce volume and preload), and centrally acting agents.
Option A: Option A is incorrect and potentially dangerous — ARBs are equally contraindicated as ACE inhibitors in bilateral renal artery stenosis; the mechanism of AKI is identical regardless of where in the RAAS pathway the drug acts.
Option B: Option B is incorrect — there is no validated low-dose RAAS blockade strategy for bilateral renal artery stenosis; the contraindication applies regardless of dose.
Option C: Option C is incorrect — revascularization improves hypertension in many patients but does not uniformly eliminate the need for pharmacotherapy depending on the degree of chronic ischemic nephropathy already present.
Option D: Option D is incorrect — beta-blockers are not sufficient alone for long-term BP control in this setting and do not address the full hemodynamic burden of bilateral renal artery stenosis.
16. A research team examines why RAAS inhibitors reduce the rate of ESRD in diabetic nephropathy to a greater degree than equivalent BP reduction achieved with a dihydropyridine CCB. Which of the following best accounts for this mechanistic disparity?
A) ACE inhibitors have direct anti-fibrotic effects on renal tubular cells through bradykinin-mediated kinase inhibition that are independent of any hemodynamic or intraglomerular pressure effect and cannot be replicated by CCBs
B) Dihydropyridine CCBs are directly nephrotoxic at therapeutic doses through calcium overload of proximal tubular cells, which offsets any benefit from systemic BP reduction and explains the apparent inferiority in clinical trials
C) The superiority of RAAS inhibitors over CCBs in diabetic nephropathy trials is attributable entirely to differences in achieved systemic BP rather than any mechanism-specific renal effect; RAAS inhibitors are simply more potent antihypertensives in this population
D) RAAS inhibitors reduce intraglomerular hydraulic pressure through preferential efferent arteriole vasodilation, independently of systemic BP, producing a glomerular pressure reduction that CCBs — which reduce systemic pressure primarily through afferent and systemic vasodilation without equivalent efferent effect — cannot replicate; it is this intraglomerular pressure reduction that is the primary determinant of the renoprotective benefit demonstrated in clinical trials
E) RAAS inhibitors reduce albuminuria by directly polymerizing glomerular basement membrane components through an angiotensin-independent structural effect on podocyte foot processes that CCBs lack entirely
ANSWER: D
Rationale:
This question asked you to identify the mechanistic basis for the observed superiority of RAAS blockade over CCBs in slowing diabetic nephropathy progression. Option D is correct: the key mechanistic distinction is intraglomerular pressure. In diabetic nephropathy, glomerular injury is driven by glomerular hypertension — elevated hydraulic pressure within the glomerular capillaries — not only by elevated systemic BP. RAAS inhibitors preferentially dilate the efferent arteriole, reducing intraglomerular hydraulic pressure independently of their systemic BP-lowering effect. Dihydropyridine CCBs lower systemic BP by reducing afferent resistance and systemic vascular resistance but do not produce equivalent efferent vasodilation; reduced afferent resistance without proportional efferent relaxation means systemic pressure is transmitted more directly into the glomerular capillaries. The net result at equivalent systemic BP levels is that RAAS blockade produces greater intraglomerular pressure reduction, greater proteinuria reduction, and slower GFR decline — demonstrated in RENAAL, IDNT, and MICROHOPE.
Option A: Option A is incorrect — while ACE inhibitors have anti-fibrotic effects through bradykinin pathways, these are not the primary explanation for clinical trial superiority over CCBs.
Option B: Option B is incorrect — dihydropyridine CCBs are not nephrotoxic at therapeutic doses.
Option C: Option C is incorrect — multiple trials have demonstrated that the renal benefit of RAAS inhibitors exceeds what can be explained by BP reduction alone; the superiority is mechanism-specific, not merely a reflection of greater potency.
Option E: Option E is incorrect — the mechanism is hemodynamic intraglomerular pressure reduction, not direct structural modification of the glomerular basement membrane.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.